Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +35.93%
#2 Siren Siren +30.58%
#3 Purr Purr +28.61%
#4 OriginTrail OriginTrail +23.69%
#5 UnifAI Network UnifAI Network +16.95%
#6 Wrapped XPL Wrapped XPL +16.15%
#7 ApeX ApeX +15.83%
#8 龙虾 (Lobster) 龙虾 (Lobster) +14.86%
#9 DigiByte DigiByte +14.48%
#10 Morpho Morpho +14.41%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Hemab Therapeutics Holdings, Inc. Common Stock Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. Common Stock

COAG
Clasificación en acciones #21709
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm... Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Precio por acción
$50.82
Última sincronización: 2026-08-11
Capitalización bursátil
$102.09M
Cambio (1 día)
1.90%
Cambio (1 año)
-
País
US
Comercio Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

Categoría

Healthcare
Ingresos de Hemab Therapeutics Holdings, Inc. Common Stock (COAG)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Hemab Therapeutics Holdings, Inc. Common Stock, los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Hemab Therapeutics Holdings, Inc. Common Stock desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH